Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
Sponsor: AstraZeneca
ClinicalTrials ID:NCT03003962
This Phase III study evaluates durvalumab versus platinum-based chemotherapy in stage IV NSCLC patients with EGFR and ALK wild-type and high PD-L1 expression. Participants are randomized to receive either durvalumab or one of several chemotherapy regimens. The primary objectives are to compare overall survival in all patients and those at low risk of early mortality.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type and with PD-L1 high expression (PEARL)
Description
Patients with stage IV NSCLC will be randomized in a 1:1 ratio to 2 treatment arms (durvalumab or SOC therapy). The dual primary objectives of this study are to assess the efficacy of durvalumab versus SoC in terms of OS (Overall Survival) in all randomized patients and in patients who are at low risk of EM (early mortality)
Eligibility Criteria
Exclusion Criteria
- Prior chemotherapy or any other systemic therapy for advanced NSCLC
- Prior exposure to immune-mediated therapy, including, but not limited to, other anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), anti-programmed cell death1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti PD-L2 antibodies, excluding therapeutic anticancer vaccines
- Brain metastases or spinal cord compression unless the patient is stable and off steroids for at least 14 days prior to start of study treatment
- Mixed small-cell lung cancer and NSCLC histology, sarcomatoid variant
- Active or prior documented autoimmune or inflammatory disorders (e.g., colitis or Crohn's disease]
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Research Site | 92801 | Anaheim | California |
Get This Program In Your Inbox
You can sign up and apply your patients for this program.